Avelumab binds PD-L1 on target cells and, via its IgG1 Fc, engages Fcγ receptors on NK cells to trigger antibody-dependent cellular cytotoxicity (ADCC), killing PD-L1–expressing cells; it also blocks PD-1/PD-L1 to enhance T-cell killing (indirect).